Conditions: Hepatitis C Cirrhosis
Keywords: cirrhosis hepatitis C
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 15
Healthy volunteers: no

Brief summary:
The main goal of this study is to prevent liver allograft infection with Hepatitis C virus in hepatitis C positive patients undergoing liver transplantation. The hypothesis is that patients who receive ribavirin immediately before transplant and intravenous interferon alfa 2b during the anhepatic phase(while the liver is removed)will have sustained virologic response post liver transplant.

Detailed description:
The study is evaluating intravenous interferon given during the anhepatic phase of lvier transplant. Ribavirin was given as well. Serial measurements for HCV RNA were determined 12, 24 72, 96 hrs and 4 weeks after liver transplant.

Arms:
arm 1: IV interferon oral ribavirin arm 2: standard of care

Interventions: intervention 1: IV interferon
Intervention descriptions: intervention 1: IV interferon 5MU during anhepatic phase

Protocol document: